Evercore Begins Coverage on Benitec Biopharma (NASDAQ:BNTC)

Posted by Stanley Muller on May 12th, 2026

Stock analysts at Evercore assumed coverage on shares of Benitec Biopharma (NASDAQ:BNTC – Get Free Report) in a report released on Tuesday. The firm set an “outperform” rating and a $25.00 price target on the biotechnology company’s stock. Evercore’s price objective would indicate a potential upside of 106.95% from the stock’s previous close.

Several other analysts have also recently commented on BNTC. TD Cowen restated a “buy” rating on shares of Benitec Biopharma in a report on Monday, March 9th. HC Wainwright restated a “buy” rating and issued a $32.00 price target on shares of Benitec Biopharma in a report on Monday, March 9th. Wall Street Zen cut Benitec Biopharma from a “hold” rating to a “sell” rating in a report on Saturday, February 14th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Benitec Biopharma in a report on Monday, April 20th. Six equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $27.00.

Read Our Latest Stock Report on BNTC

Benitec Biopharma Price Performance

BNTC opened at $12.08 on Tuesday. The stock has a market capitalization of $414.95 million, a price-to-earnings ratio of -10.60 and a beta of 0.28. The business has a 50-day moving average of $11.77 and a two-hundred day moving average of $12.40. Benitec Biopharma has a 12 month low of $9.85 and a 12 month high of $17.15.

Benitec Biopharma (NASDAQ:BNTC – Get Free Report) last posted its quarterly earnings results on Thursday, February 12th. The biotechnology company reported ($0.26) EPS for the quarter, missing the consensus estimate of ($0.23) by ($0.03). Equities research analysts anticipate that Benitec Biopharma will post -1.05 earnings per share for the current year.

Institutional Trading of Benitec Biopharma

Institutional investors have recently modified their holdings of the company. BNP Paribas Financial Markets grew its holdings in shares of Benitec Biopharma by 44.5% during the 3rd quarter. BNP Paribas Financial Markets now owns 2,937 shares of the biotechnology company’s stock worth $41,000 after purchasing an additional 904 shares during the period. Truvestments Capital LLC grew its holdings in shares of Benitec Biopharma by 156.5% during the 4th quarter. Truvestments Capital LLC now owns 3,834 shares of the biotechnology company’s stock worth $52,000 after purchasing an additional 2,339 shares during the period. Russell Investments Group Ltd. purchased a new stake in shares of Benitec Biopharma during the 3rd quarter worth about $79,000. JPMorgan Chase & Co. purchased a new stake in shares of Benitec Biopharma during the 2nd quarter worth about $80,000. Finally, Bank of America Corp DE grew its holdings in shares of Benitec Biopharma by 2,255.8% during the 2nd quarter. Bank of America Corp DE now owns 6,879 shares of the biotechnology company’s stock worth $80,000 after purchasing an additional 6,587 shares during the period. Hedge funds and other institutional investors own 52.19% of the company’s stock.

About Benitec Biopharma

(Get Free Report)

Benitec Biopharma Ltd (NASDAQ: BNTC) is a clinical-stage biotechnology company developing gene-silencing therapies for serious human diseases. The company’s proprietary DNA-directed RNA interference (ddRNAi) platform is designed to enable sustained expression of small RNA molecules that specifically target and silence disease-causing genes. By integrating RNAi sequences directly into DNA constructs, ddRNAi aims to provide a long-term therapeutic effect from a single administration.

Benitec’s lead programs include development of ddRNAi candidates for chronic hepatitis B virus infection and for certain ocular conditions.